Abstract: The invention is based on the discovery that combination therapy with 2-deoxyglucose, methotrexate, and wogonin provides a synergistic therapeutic effect in selectively killing cancer cells. Advantageously, the disclosed combinatorial therapy does not adversely affect normal, healthy cells. Although the individual compounds have been previously used in cancer treatment, the cited combination has been surprisingly found to selectively kill cancer cells, while not adversely affecting normal, healthy cells, especially those of the immune system. Further, the combination of the compounds produces a synergistic effect, with increased killing of cancer cells compared to each compound alone. Importantly, the combination caused the dying cancer cells to release three key markers of immunogenic cell death: HMGB1, ATP and calreticulin. Immunogenic cell death attracts and activates immune cells against cancers.

Abstract: The invention is based on the discovery that combination therapy with 2-deoxyglucose, methotrexate, and wogonin provides a synergistic therapeutic effect in selectively killing cancer cells. Advantageously, the disclosed combinatorial therapy does not adversely affect normal, healthy cells. Although the individual compounds have been previously used in cancer treatment, the cited combination has been surprisingly found to selectively kill cancer cells, while not adversely affecting normal, healthy cells, especially those of the immune system. Further, the combination of the compounds produces a synergistic effect, with increased killing of cancer cells compared to each compound alone. Importantly, the combination caused the dying cancer cells to release three key markers of immunogenic cell death: HMGB1, ATP and calreticulin. Immunogenic cell death attracts and activates immune cells against cancers.

Abstract: The presently disclosed subject matter is directed to an assay that detects and quantitatively determines the activity of a lytic peptide that exhibits antimicrobial activity, such as LL-37. Particularly, the assay comprises inducing and/or transfecting bacteria to produce high levels of an enzyme, such as ?-galactosidase. The bacteria are then preserved by lyophilization. After a desired amount of time, the bacteria are hydrated with a target sample from a subject suspected of having a specific disease or disorder characterized by an increase in levels of lytic peptide. In the presence of lytic peptide, the enzyme is released from the interior of the bacteria, which can then be detected by alteration of the enzyme substrate. In the absence of lytic peptide, the enzyme remains within the bacteria and no detection of the enzyme occurs.

Abstract: The presently disclosed subject matter is directed to an assay that detects and quantitatively determines the activity of a lytic peptide that exhibits antimicrobial activity, such as LL-37. Particularly, the assay comprises inducing and/or transfecting bacteria to produce high levels of an enzyme, such as ?-galactosidase. The bacteria are then preserved by lyophilization. After a desired amount of time, the bacteria are hydrated with a target sample from a subject suspected of having a specific disease or disorder characterized by an increase in levels of lytic peptide. In the presence of lytic peptide, the enzyme is released from the interior of the bacteria, which can then be detected by alteration of the enzyme substrate. In the absence of lytic peptide, the enzyme remains within the bacteria and no detection of the enzyme occurs.

Abstract: The presently disclosed subject matter is directed to an assay that detects and quantitatively determines the activity of a lytic peptide that exhibits antimicrobial activity, such as LL-37. Particularly, the assay comprises inducing and/or transfecting bacteria to produce high levels of an enzyme, such as ?-galactosidase. The bacteria are then preserved by lyophilization. After a desired amount of time, the bacteria are hydrated with a target sample from a subject suspected of having a specific disease or disorder characterized by an increase in levels of lytic peptide. In the presence of lytic peptide, the enzyme is released from the interior of the bacteria, which can then be detected by alteration of the enzyme substrate. In the absence of lytic peptide, the enzyme remains within the bacteria and no detection of the enzyme occurs.

Abstract: Aspects of the present invention relate to automatic impedance measurements between one or more electrodes in a set of electrodes that may be associated with a lead of an implanted device. A voltage measurement that is associated with a stimulation pulse between the two electrodes may be made. The voltage measurement may be used to determine the impedance between the two electrodes. The impedance measurement may be made for each possible pair of electrodes in the set of electrodes. The impedance measurements may be displayed to a clinician on a user interface.

Abstract: A circular saw assembly of the type that includes a motor housing, a handle coupled to the motor housing, a generally circular saw blade disposed within a blade housing at a first end of the motor housing, and a foot member through which the blade extends for guiding the saw assembly along a work surface, where the circular saw assembly including a depth of cut locking system and an angle of cut locking system. The depth of cut locking system includes an arcuate bracket with an arcuate slot, and an engagement member extends through the slot and is operatively connected to the motor housing and slideable in the arcuate slot. The angle of cut locking system includes a bracket having an arcuate slot and an engagement member movable in the slot and configured to the bracket. A biasing member is provided to bias the engagement member, and at least one detent recess is provided to retain the engagement member therein.

Abstract: A repositionable operating lever including a lever body having a handle and a generally hollow cylindrical housing, an inner end portion of which has a multi-faced wall configured to engage a multi-faced head portion of an adjusting member, an adjusting member positioned in the cylindrical housing and having a multi-faced head portion engaging the multi-faced wall of the inner end portion, a generally cylindrical end piece configured to fit within an outer end portion of the cylindrical housing, a biasing member having a inner end and a outer end, and wherein the lever body is capable of being moved in the outer direction relative to the adjusting member by manipulation overcoming the biasing force whereby the multi-faced head portion and the multi-faced wall disengage from one another, permitting relative rotation of the lever body and the adjusting member to reposition the lever body on the adjusting member.

Abstract: The present invention automates the adjustment of an amplitude of stimulated pulses that are generated by an implanted device. Apparatus comprises a processor that communicates with the implanted device over a communications channel through a communications module. The apparatus enables the clinician to select a pair of electrodes that is contained on a lead of the implanted device. Corresponding to each iteration of the process, the processor sends a command to the implanted device in order to increment the amplitude of the stimulation pulse between the selected electrodes. Each iteration of the process corresponds to the apparatus incrementing the current value by a predetermined incremental value that can be selected by the clinician. When the current value of the amplitude equals the target value, the process is halted. Additionally, the clinician can halt process during the execution of the process by instructing the apparatus.